Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970504 | 1.00 | ALDH1A1 (0.40) | ALDH1A1KMT2AMAPTTAS2R14ACLY | |
| SCHEMBL20111185 | 0.89 | POLB (0.36) | ALDH1A1KMT2AMAPT | |
| SCHEMBL20111175 | 0.89 | POLB (0.36) | ALDH1A1KMT2AMAPT | |
| SCHEMBL19970508 | 0.88 | TAS2R14 (0.34) | KMT2ATAS2R14TP53AKR1C3 | |
| SCHEMBL19970486 | 0.88 | TAS2R14 (0.34) | KMT2ATAS2R14TP53AKR1C3 | |
| SCHEMBL19970476 | 0.81 | GRM2 (0.38) | ALDH1A1KMT2A | |
| SCHEMBL19970507 | 0.81 | P2RX7 (0.31) | — | |
| SCHEMBL20111184 | 0.80 | KMT2A (0.37) | ALDH1A1KMT2AMAPTTP53LMNA | |
| SCHEMBL19970525 | 0.78 | LMNA (0.36) | ALDH1A1KMT2AMAPTLMNAGAA | |
| SCHEMBL19970497 | 0.75 | ALDH1A1 (0.37) | ALDH1A1KMT2AMAPTSLC5A2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118708-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3296296-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118708-A1 | CYCLIC COMPOUND | TLR4, TLR3, TLR9 | ALDH1A1 973/4885KMT2A 3879/4885MAPT 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.